Judith Christina Maro, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Product Surveillance, Postmarketing | 14 | 2024 | 463 | 4.370 |
Why?
|
Herpes Zoster Vaccine | 3 | 2023 | 49 | 2.180 |
Why?
|
Pharmacoepidemiology | 6 | 2024 | 351 | 1.990 |
Why?
|
Herpes Zoster | 3 | 2023 | 252 | 1.890 |
Why?
|
Pregnancy Outcome | 4 | 2024 | 2972 | 1.300 |
Why?
|
Data Mining | 10 | 2024 | 561 | 1.280 |
Why?
|
United States Food and Drug Administration | 15 | 2024 | 1672 | 1.200 |
Why?
|
Adverse Drug Reaction Reporting Systems | 8 | 2024 | 497 | 1.150 |
Why?
|
Guillain-Barre Syndrome | 2 | 2022 | 128 | 0.810 |
Why?
|
Databases, Factual | 15 | 2024 | 8068 | 0.800 |
Why?
|
Urticaria | 1 | 2022 | 151 | 0.740 |
Why?
|
Sentinel Surveillance | 6 | 2024 | 292 | 0.680 |
Why?
|
Papillomavirus Vaccines | 3 | 2021 | 497 | 0.670 |
Why?
|
Vaccination | 7 | 2024 | 3434 | 0.660 |
Why?
|
Pain, Intractable | 1 | 2020 | 132 | 0.640 |
Why?
|
Vaccines, Attenuated | 2 | 2019 | 314 | 0.620 |
Why?
|
Food | 1 | 2023 | 766 | 0.610 |
Why?
|
Computer Simulation | 4 | 2024 | 6260 | 0.600 |
Why?
|
Exanthema | 1 | 2022 | 502 | 0.590 |
Why?
|
Vaccines | 3 | 2014 | 842 | 0.570 |
Why?
|
Propensity Score | 6 | 2022 | 1971 | 0.540 |
Why?
|
Research Design | 4 | 2024 | 6210 | 0.540 |
Why?
|
Insurance Claim Review | 2 | 2024 | 744 | 0.530 |
Why?
|
Drug Interactions | 1 | 2020 | 1419 | 0.500 |
Why?
|
Dermatitis, Atopic | 1 | 2022 | 734 | 0.490 |
Why?
|
Myocarditis | 1 | 2022 | 802 | 0.480 |
Why?
|
Drug Approval | 2 | 2020 | 820 | 0.470 |
Why?
|
Papillomavirus Infections | 3 | 2021 | 1639 | 0.450 |
Why?
|
Orphan Drug Production | 1 | 2014 | 48 | 0.450 |
Why?
|
Sample Size | 3 | 2024 | 845 | 0.440 |
Why?
|
Drug Monitoring | 1 | 2019 | 963 | 0.420 |
Why?
|
Cardiovascular Agents | 1 | 2019 | 849 | 0.420 |
Why?
|
Models, Immunological | 1 | 2014 | 516 | 0.400 |
Why?
|
Risk | 4 | 2019 | 9606 | 0.390 |
Why?
|
Computer Communication Networks | 3 | 2020 | 292 | 0.370 |
Why?
|
Influenza, Human | 3 | 2023 | 1543 | 0.370 |
Why?
|
Pharmaceutical Preparations | 4 | 2023 | 1085 | 0.370 |
Why?
|
International Classification of Diseases | 3 | 2021 | 935 | 0.360 |
Why?
|
Incidence | 8 | 2024 | 21526 | 0.360 |
Why?
|
Data Collection | 1 | 2020 | 3321 | 0.360 |
Why?
|
United States | 27 | 2025 | 72971 | 0.360 |
Why?
|
Warfarin | 1 | 2019 | 1493 | 0.350 |
Why?
|
Rare Diseases | 1 | 2014 | 630 | 0.310 |
Why?
|
Seizures | 2 | 2019 | 2996 | 0.310 |
Why?
|
Poisson Distribution | 2 | 2024 | 507 | 0.300 |
Why?
|
Cohort Studies | 10 | 2024 | 41718 | 0.300 |
Why?
|
Electronic Health Records | 8 | 2024 | 4881 | 0.250 |
Why?
|
Humans | 52 | 2025 | 767040 | 0.240 |
Why?
|
Control Groups | 1 | 2024 | 107 | 0.230 |
Why?
|
Nitrosamines | 1 | 2024 | 86 | 0.230 |
Why?
|
Teratogens | 1 | 2024 | 119 | 0.230 |
Why?
|
Analgesics, Opioid | 1 | 2020 | 3837 | 0.220 |
Why?
|
Papillomaviridae | 2 | 2021 | 1139 | 0.220 |
Why?
|
Models, Statistical | 3 | 2014 | 5098 | 0.210 |
Why?
|
Registries | 2 | 2022 | 8351 | 0.210 |
Why?
|
Drug Contamination | 1 | 2024 | 151 | 0.210 |
Why?
|
Medical Records Systems, Computerized | 1 | 2009 | 1196 | 0.210 |
Why?
|
Herpesvirus 3, Human | 1 | 2023 | 159 | 0.190 |
Why?
|
Health Services Research | 1 | 2009 | 1815 | 0.190 |
Why?
|
Tinnitus | 1 | 2024 | 197 | 0.190 |
Why?
|
Losartan | 1 | 2023 | 262 | 0.190 |
Why?
|
Pregnancy | 7 | 2024 | 30238 | 0.190 |
Why?
|
Pregnancy Trimester, First | 2 | 2022 | 917 | 0.180 |
Why?
|
Anticonvulsants | 2 | 2022 | 1921 | 0.180 |
Why?
|
Respiratory Syncytial Virus, Human | 1 | 2023 | 150 | 0.180 |
Why?
|
Oxymorphone | 1 | 2020 | 6 | 0.180 |
Why?
|
Data Interpretation, Statistical | 2 | 2021 | 2698 | 0.170 |
Why?
|
Drug Evaluation | 1 | 2021 | 641 | 0.170 |
Why?
|
Decision Making, Organizational | 1 | 2020 | 136 | 0.170 |
Why?
|
Vaccines, Synthetic | 1 | 2022 | 621 | 0.160 |
Why?
|
Incretins | 1 | 2019 | 100 | 0.160 |
Why?
|
Oxycodone | 1 | 2020 | 144 | 0.160 |
Why?
|
Stillbirth | 1 | 2022 | 381 | 0.150 |
Why?
|
Software | 2 | 2018 | 4472 | 0.150 |
Why?
|
Live Birth | 1 | 2022 | 516 | 0.150 |
Why?
|
Proportional Hazards Models | 2 | 2025 | 12536 | 0.150 |
Why?
|
Myocardial Infarction | 1 | 2019 | 11513 | 0.150 |
Why?
|
Contraceptives, Oral, Combined | 1 | 2018 | 118 | 0.150 |
Why?
|
Time Factors | 6 | 2021 | 40154 | 0.150 |
Why?
|
Pandemics | 3 | 2021 | 8736 | 0.140 |
Why?
|
Technology | 1 | 2019 | 296 | 0.140 |
Why?
|
Hypoglycemic Agents | 2 | 2019 | 3108 | 0.140 |
Why?
|
Diabetic Ketoacidosis | 1 | 2019 | 252 | 0.130 |
Why?
|
Cluster Analysis | 1 | 2022 | 2721 | 0.130 |
Why?
|
Decision Support Techniques | 1 | 2024 | 2006 | 0.120 |
Why?
|
Birth Weight | 1 | 2022 | 2122 | 0.110 |
Why?
|
Medical Records | 1 | 2019 | 1409 | 0.110 |
Why?
|
Seizures, Febrile | 1 | 2014 | 109 | 0.110 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2021 | 1372 | 0.110 |
Why?
|
Influenza Vaccines | 2 | 2024 | 780 | 0.110 |
Why?
|
Infant | 4 | 2022 | 36485 | 0.100 |
Why?
|
Canada | 3 | 2024 | 2127 | 0.100 |
Why?
|
Female | 17 | 2024 | 396660 | 0.100 |
Why?
|
Pancreatitis | 1 | 2019 | 1087 | 0.100 |
Why?
|
Mothers | 1 | 2022 | 2209 | 0.100 |
Why?
|
Algorithms | 5 | 2021 | 14098 | 0.100 |
Why?
|
Denmark | 2 | 2024 | 776 | 0.090 |
Why?
|
Epidemiologic Research Design | 1 | 2014 | 368 | 0.090 |
Why?
|
Electronics | 2 | 2022 | 316 | 0.090 |
Why?
|
Hyperlipoproteinemia Type II | 1 | 2014 | 396 | 0.080 |
Why?
|
Pilot Projects | 2 | 2020 | 8732 | 0.080 |
Why?
|
Anaphylaxis | 1 | 2015 | 738 | 0.080 |
Why?
|
Kidney Diseases | 1 | 2019 | 2099 | 0.080 |
Why?
|
Observation | 1 | 2009 | 310 | 0.070 |
Why?
|
Risk Assessment | 3 | 2024 | 24299 | 0.070 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2020 | 2299 | 0.070 |
Why?
|
Monte Carlo Method | 1 | 2011 | 1250 | 0.060 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2018 | 2038 | 0.060 |
Why?
|
Financing, Government | 1 | 2009 | 473 | 0.060 |
Why?
|
Venous Thromboembolism | 1 | 2018 | 1883 | 0.060 |
Why?
|
Reproducibility of Results | 2 | 2024 | 20169 | 0.060 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 2019 | 3449 | 0.060 |
Why?
|
Drug Recalls | 1 | 2024 | 20 | 0.060 |
Why?
|
Young Adult | 6 | 2021 | 59980 | 0.060 |
Why?
|
Logistic Models | 1 | 2019 | 13284 | 0.060 |
Why?
|
HIV Infections | 2 | 2020 | 17542 | 0.050 |
Why?
|
Prospective Studies | 4 | 2021 | 54886 | 0.050 |
Why?
|
Adolescent | 6 | 2021 | 89046 | 0.050 |
Why?
|
Hypertension | 1 | 2023 | 8615 | 0.050 |
Why?
|
Aged | 5 | 2024 | 171319 | 0.050 |
Why?
|
Infant, Newborn | 1 | 2022 | 26396 | 0.050 |
Why?
|
Adult | 9 | 2024 | 223317 | 0.050 |
Why?
|
Treatment Outcome | 2 | 2021 | 65295 | 0.050 |
Why?
|
Male | 9 | 2024 | 364203 | 0.050 |
Why?
|
Hospitalization | 1 | 2021 | 10815 | 0.050 |
Why?
|
Decision Making | 1 | 2014 | 3951 | 0.050 |
Why?
|
Patient Acceptance of Health Care | 1 | 2014 | 3232 | 0.040 |
Why?
|
Biological Therapy | 1 | 2021 | 140 | 0.040 |
Why?
|
Clinical Coding | 1 | 2021 | 187 | 0.040 |
Why?
|
Glycosides | 1 | 2019 | 99 | 0.040 |
Why?
|
Middle Aged | 7 | 2024 | 223233 | 0.040 |
Why?
|
Sensitivity and Specificity | 1 | 2014 | 14672 | 0.040 |
Why?
|
Biphenyl Compounds | 1 | 2023 | 1026 | 0.040 |
Why?
|
Predictive Value of Tests | 1 | 2014 | 15424 | 0.040 |
Why?
|
Child | 3 | 2021 | 80771 | 0.040 |
Why?
|
Fertility | 1 | 2022 | 771 | 0.030 |
Why?
|
Tetrazoles | 1 | 2023 | 923 | 0.030 |
Why?
|
Information Dissemination | 1 | 2025 | 1142 | 0.030 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2023 | 1515 | 0.030 |
Why?
|
Angiotensin Receptor Antagonists | 1 | 2023 | 1065 | 0.030 |
Why?
|
Bayes Theorem | 1 | 2024 | 2353 | 0.030 |
Why?
|
Heart Failure | 1 | 2019 | 11877 | 0.030 |
Why?
|
Vaccines, Inactivated | 1 | 2015 | 186 | 0.030 |
Why?
|
Communicable Disease Control | 1 | 2021 | 856 | 0.030 |
Why?
|
Immunization | 1 | 2018 | 1218 | 0.030 |
Why?
|
Prevalence | 2 | 2021 | 15851 | 0.030 |
Why?
|
HIV | 1 | 2020 | 1591 | 0.030 |
Why?
|
Gestational Age | 1 | 2022 | 3618 | 0.030 |
Why?
|
Retrospective Studies | 4 | 2024 | 81659 | 0.030 |
Why?
|
Odds Ratio | 1 | 2025 | 9660 | 0.030 |
Why?
|
Statistics as Topic | 1 | 2018 | 2350 | 0.020 |
Why?
|
Risk Factors | 2 | 2018 | 74886 | 0.020 |
Why?
|
Natural Language Processing | 1 | 2019 | 1202 | 0.020 |
Why?
|
Health Policy | 1 | 2021 | 2698 | 0.020 |
Why?
|
Antiviral Agents | 1 | 2021 | 3070 | 0.020 |
Why?
|
Inpatients | 1 | 2018 | 2563 | 0.020 |
Why?
|
Biomedical Research | 1 | 2020 | 3464 | 0.010 |
Why?
|
Anti-HIV Agents | 1 | 2019 | 4567 | 0.010 |
Why?
|
Aged, 80 and over | 1 | 2024 | 59548 | 0.010 |
Why?
|
Emergency Service, Hospital | 1 | 2018 | 7871 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2019 | 39317 | 0.010 |
Why?
|
Child, Preschool | 1 | 2015 | 42606 | 0.010 |
Why?
|